MORGAN STANLEY: JP MORGAN INCREASES TARGET PRICE TO $173, UP FROM $162
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 16 2026
0mins
Source: moomoo
Target Price Increase: JP Morgan has raised its target price for a specific stock from $162 to $173.
Market Implications: This adjustment reflects JP Morgan's positive outlook on the stock's performance in the market.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy MS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on MS
Wall Street analysts forecast MS stock price to rise
14 Analyst Rating
7 Buy
7 Hold
0 Sell
Moderate Buy
Current: 176.590
Low
132.00
Averages
185.00
High
219.00
Current: 176.590
Low
132.00
Averages
185.00
High
219.00
About MS
Morgan Stanley is a global financial services company. The Company is engaged in providing a range of investment banking, securities, wealth management and investment management services. Its segments include Institutional Securities, Wealth Management and Investment Management. Its Institutional Securities segment provides a variety of products and services to corporations, governments, financial institutions and ultra-high net worth clients. Its Wealth Management segment provides an array of financial services and solutions to individual investors and small to medium-sized businesses and institutions. Its Investment Management segment provides a range of investment strategies and products that span geographies, asset classes, and public and private markets to a diverse group of clients across institutional and intermediary channels. Its investment banking services consist of capital raising and financial advisory services, including the underwriting of debt and other products.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
U.S. Drug Development Faces Bottlenecks
- Drug Development Lag: FDA Commissioner Marty Makary highlighted that the U.S. is falling behind China in early-stage drug development, particularly in phase one clinical trials conducted in 2024, indicating a significant competitive disadvantage that necessitates reforms to accelerate trial processes for new treatments.
- Process Bottlenecks: Makary pointed out three major bottlenecks, including hospital contracting, ethical reviews, and approval processes, which he described as 'clunky processes' that hinder the efficiency of drug trials in the U.S., impacting its competitiveness against faster-moving countries.
- Collaboration Opportunities: The FDA is exploring partnerships with health systems and academic medical centers to streamline the pre-IND process, allowing for consultations before formal application submissions, thereby enhancing the efficiency and success rates of drug development.
- China's Rise: Data shows that China now conducts more clinical trials than the U.S. and is projected to account for 35% of FDA new drug approvals by 2040, putting pressure on U.S. policymakers to take action to boost domestic innovation.
See More
Morgan Stanley Reduces Transaction Fees to 2.5%
- Fee Reduction: Morgan Stanley Wealth Management announces that transaction fees for both buy and sell sides on EquityZen will be reduced from 5% to 2.5%, allowing more clients to transact at lower costs, thereby facilitating wealth accumulation.
- Enhanced Market Competitiveness: This fee adjustment not only makes EquityZen's 'Express Deals' more attractive but also lowers the minimum investment threshold to $5,000, further expanding investor participation and enhancing market liquidity.
- Strategic Acquisition Impact: Morgan Stanley's acquisition of EquityZen in 2026 aims to integrate its private market ecosystem to enhance client experience and provide comprehensive solutions, thereby gaining an edge in the competitive wealth management sector.
- Technology-Driven Innovation: EquityZen leverages its industry-leading technology platform to democratize private markets, and with the backing of Morgan Stanley's resources and expertise, it enhances the overall experience for clients and shareholders, solidifying its market position.
See More
Supreme Court Set to Rule on Tariff Authority
- Tariff Legality Review: The Supreme Court is poised to rule on the legality of tariffs imposed by President Trump under the International Emergency Economic Powers Act (IEEPA), which could significantly impact pricing and margin strategies for consumer giants like Costco and Procter & Gamble.
- Potential EBITDA Uplift: Morgan Stanley's analysis suggests that a rollback or limitation of IEEPA-based tariffs could lead to a mid-single-digit uplift in EBITDA for affected retailers, providing notable margin support amid economic pressures.
- Retailer Response Strategies: While awaiting the ruling, retailers such as Costco and Amazon are leveraging strong negotiating power and value-oriented business models to navigate tariff pressures, ensuring they protect consumer value even as costs rise.
- Optimistic Market Outlook: Despite tariffs remaining a defining feature of the trade landscape, analysts believe that consumer spending may receive additional support from tax refunds, making the retail and consumer staples sectors attractive investment opportunities.
See More
Morgan Stanley Reduces Fees for Private Market Investments via EquityZen
- Fee Reduction: Morgan Stanley is halving fees for investments in private companies, making it more attractive for wealthy clients to invest in non-publicly traded businesses.
- Acquisition Impact: This decision follows the recent acquisition of EquityZen, a platform that facilitates trading of private shares, enhancing Morgan Stanley's offerings in the private investment space.
See More
Investment Outlook for the U.S. Healthcare Sector in 2024
- Healthcare Sector Size: U.S. healthcare spending is projected to exceed $5.3 trillion in 2024, representing nearly one-fifth of the U.S. economy, highlighting the sector's immense investment potential and attracting long-term investor interest.
- AbbVie's Growth Potential: AbbVie (ABBV), with its diverse treatment portfolio and over 50 years of dividend growth history, is expected to achieve over 17% annual earnings growth, making it a top choice for investors.
- Eli Lilly's Market Leadership: Eli Lilly (LLY) has established itself as a leader in the obesity drug market, with tirzepatide driving success; the market is expected to reach $144 billion by 2030, with anticipated annual earnings growth of 25%.
- Bristol Myers Squibb's Challenges and Opportunities: Despite facing patent expirations, Bristol Myers Squibb (BMY) has a strong oncology pipeline and a projected 15% annual earnings growth, indicating significant upside potential for investors.
See More
Alternative Investments Currently Favored by Financial Experts
Growth of Alternative Investments: Alternative investments have gained popularity since the 1990s, especially among pensions and endowments, and are now increasingly included in individual investors' portfolios due to easier access and a wider range of asset classes.
Impact of Financial Crisis: The 2008-09 financial crisis led to more companies remaining private longer, further driving interest in alternative investments.
Challenges in Selection: With trillions of dollars pursuing private investments globally, identifying successful opportunities has become more complex for investors.
Expert Insights: Investment professionals are currently sharing their preferences for specific types of alternative investments amidst the growing market.
See More
U.S. Drug Development Faces Bottlenecks
- Drug Development Lag: FDA Commissioner Marty Makary highlighted that the U.S. is falling behind China in early-stage drug development, particularly in phase one clinical trials conducted in 2024, indicating a significant competitive disadvantage that necessitates reforms to accelerate trial processes for new treatments.
- Process Bottlenecks: Makary pointed out three major bottlenecks, including hospital contracting, ethical reviews, and approval processes, which he described as 'clunky processes' that hinder the efficiency of drug trials in the U.S., impacting its competitiveness against faster-moving countries.
- Collaboration Opportunities: The FDA is exploring partnerships with health systems and academic medical centers to streamline the pre-IND process, allowing for consultations before formal application submissions, thereby enhancing the efficiency and success rates of drug development.
- China's Rise: Data shows that China now conducts more clinical trials than the U.S. and is projected to account for 35% of FDA new drug approvals by 2040, putting pressure on U.S. policymakers to take action to boost domestic innovation.
See More
Morgan Stanley Reduces Transaction Fees to 2.5%
- Fee Reduction: Morgan Stanley Wealth Management announces that transaction fees for both buy and sell sides on EquityZen will be reduced from 5% to 2.5%, allowing more clients to transact at lower costs, thereby facilitating wealth accumulation.
- Enhanced Market Competitiveness: This fee adjustment not only makes EquityZen's 'Express Deals' more attractive but also lowers the minimum investment threshold to $5,000, further expanding investor participation and enhancing market liquidity.
- Strategic Acquisition Impact: Morgan Stanley's acquisition of EquityZen in 2026 aims to integrate its private market ecosystem to enhance client experience and provide comprehensive solutions, thereby gaining an edge in the competitive wealth management sector.
- Technology-Driven Innovation: EquityZen leverages its industry-leading technology platform to democratize private markets, and with the backing of Morgan Stanley's resources and expertise, it enhances the overall experience for clients and shareholders, solidifying its market position.
See More
Supreme Court Set to Rule on Tariff Authority
- Tariff Legality Review: The Supreme Court is poised to rule on the legality of tariffs imposed by President Trump under the International Emergency Economic Powers Act (IEEPA), which could significantly impact pricing and margin strategies for consumer giants like Costco and Procter & Gamble.
- Potential EBITDA Uplift: Morgan Stanley's analysis suggests that a rollback or limitation of IEEPA-based tariffs could lead to a mid-single-digit uplift in EBITDA for affected retailers, providing notable margin support amid economic pressures.
- Retailer Response Strategies: While awaiting the ruling, retailers such as Costco and Amazon are leveraging strong negotiating power and value-oriented business models to navigate tariff pressures, ensuring they protect consumer value even as costs rise.
- Optimistic Market Outlook: Despite tariffs remaining a defining feature of the trade landscape, analysts believe that consumer spending may receive additional support from tax refunds, making the retail and consumer staples sectors attractive investment opportunities.
See More
Morgan Stanley Reduces Fees for Private Market Investments via EquityZen
- Fee Reduction: Morgan Stanley is halving fees for investments in private companies, making it more attractive for wealthy clients to invest in non-publicly traded businesses.
- Acquisition Impact: This decision follows the recent acquisition of EquityZen, a platform that facilitates trading of private shares, enhancing Morgan Stanley's offerings in the private investment space.
See More
Investment Outlook for the U.S. Healthcare Sector in 2024
- Healthcare Sector Size: U.S. healthcare spending is projected to exceed $5.3 trillion in 2024, representing nearly one-fifth of the U.S. economy, highlighting the sector's immense investment potential and attracting long-term investor interest.
- AbbVie's Growth Potential: AbbVie (ABBV), with its diverse treatment portfolio and over 50 years of dividend growth history, is expected to achieve over 17% annual earnings growth, making it a top choice for investors.
- Eli Lilly's Market Leadership: Eli Lilly (LLY) has established itself as a leader in the obesity drug market, with tirzepatide driving success; the market is expected to reach $144 billion by 2030, with anticipated annual earnings growth of 25%.
- Bristol Myers Squibb's Challenges and Opportunities: Despite facing patent expirations, Bristol Myers Squibb (BMY) has a strong oncology pipeline and a projected 15% annual earnings growth, indicating significant upside potential for investors.
See More
Alternative Investments Currently Favored by Financial Experts
Growth of Alternative Investments: Alternative investments have gained popularity since the 1990s, especially among pensions and endowments, and are now increasingly included in individual investors' portfolios due to easier access and a wider range of asset classes.
Impact of Financial Crisis: The 2008-09 financial crisis led to more companies remaining private longer, further driving interest in alternative investments.
Challenges in Selection: With trillions of dollars pursuing private investments globally, identifying successful opportunities has become more complex for investors.
Expert Insights: Investment professionals are currently sharing their preferences for specific types of alternative investments amidst the growing market.
See More
